Syngene International Q3 Profit Plunges 89% Amidst Biologics Impact

• Syngene International reported an 88.5% year-on-year drop in net profit to ₹15 crore for Q3 FY26, down from ₹131 crore.
• Revenue for the quarter declined 2.8% YoY to ₹917 crore, while EBITDA fell 25.9% to ₹209.2 crore.
• The company commissioned a new commercial-scale facility for liquid-filled hard gelatin capsules, enhancing its oral solid dosage platform.
• Advanced chemistry capabilities were expanded at the Hyderabad site with new catalytic screening and flow chemistry laboratories.
• The Q3 performance was significantly impacted by a single product from a large-molecule biologics client, though other business areas showed steady progress.

Why It Matters: Syngene International's Q3 profit sharply declined due to a specific biologics product, despite other business growth.